Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2019 | Elderly DLBCL updates

Graham Collins • 7 Dec 2019
ASH 2019
Anemias B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Cyclophosphamide Doxorubicin Lenalidomide Prednisone Vincristine

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares his highlights from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Dr Collins specifically discusses news relating to elderly patients with diffuse large B-cell lymphoma (DLBCL).

More from Graham Collins

Current treatment approaches for relapsed Hodgkin lymphoma & challenges that remain
3:22
Current treatment approaches for relapsed Hodgkin lymphoma & challenges that remain
Graham Collins • 28 May 2025
How the Hodgkin lymphoma treatment landscape has evolved: BV-AVD, nivolumab-AVD, BrECADD & more
4:46
How the Hodgkin lymphoma treatment landscape has evolved: BV-AVD, nivolumab-AVD, BrECADD & more
Graham Collins • 28 May 2025
Long-term surveillance for cardiac toxicities in patients with HL treated with chemotherapy
1:34
Long-term surveillance for cardiac toxicities in patients with HL treated with chemotherapy
Graham Collins • 16 Jun 2024
Updates from the Phase II ANIMATE trial of nivolumab in R/R cHL
1:44
Updates from the Phase II ANIMATE trial of nivolumab in R/R cHL
Graham Collins • 16 Jun 2024

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Graham Collins • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Graham Collins • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Graham Collins • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Graham Collins • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals